Oxygenta Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Oxygenta Pharmaceutical's earnings have been declining at an average annual rate of -28.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 15.2% per year.
Key information
-28.6%
Earnings growth rate
-6.9%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 15.2% |
Return on equity | n/a |
Net Margin | -41.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Oxygenta Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 373 | -154 | 15 | 0 |
30 Sep 23 | 360 | -153 | 15 | 0 |
30 Jun 23 | 290 | -144 | 12 | 0 |
31 Mar 23 | 310 | -116 | 14 | 0 |
31 Dec 22 | 299 | -82 | 51 | 0 |
30 Sep 22 | 380 | -46 | 49 | 0 |
30 Jun 22 | 474 | -28 | 4 | 0 |
31 Mar 22 | 605 | -6 | 8 | 0 |
31 Dec 21 | 646 | 11 | 40 | 0 |
30 Sep 21 | 778 | 38 | 6 | 0 |
30 Jun 21 | 707 | 35 | 7 | 0 |
31 Mar 21 | 520 | 29 | 43 | 0 |
31 Dec 20 | 431 | 16 | 26 | 0 |
30 Sep 20 | 180 | -33 | 6 | 0 |
30 Jun 20 | 136 | -49 | 6 | 0 |
31 Mar 20 | 137 | -58 | 25 | 0 |
31 Dec 19 | 153 | -66 | 31 | 0 |
30 Sep 19 | 144 | -63 | 32 | 0 |
30 Jun 19 | 164 | -42 | 8 | 0 |
31 Mar 19 | 205 | -33 | 33 | 0 |
31 Dec 18 | 222 | -42 | 28 | 0 |
30 Sep 18 | 221 | -27 | 36 | 0 |
30 Jun 18 | 185 | -26 | 51 | 0 |
31 Mar 18 | 129 | -45 | 34 | 0 |
31 Dec 17 | 92 | -36 | 27 | 0 |
30 Sep 17 | 93 | -56 | 28 | 0 |
30 Jun 17 | 54 | -72 | 27 | 0 |
31 Mar 17 | 82 | -58 | 34 | 0 |
31 Dec 16 | 101 | -75 | 31 | 0 |
30 Sep 16 | 132 | -50 | 32 | 0 |
30 Jun 16 | 138 | -48 | 33 | 0 |
31 Mar 16 | 124 | -55 | 31 | 0 |
31 Dec 15 | 94 | -43 | 37 | 0 |
30 Sep 15 | 56 | -59 | 31 | 0 |
30 Jun 15 | 56 | -64 | 32 | 0 |
31 Mar 15 | 62 | -61 | 29 | 0 |
31 Dec 14 | 40 | -53 | 42 | 0 |
30 Sep 14 | 29 | -53 | 40 | 0 |
30 Jun 14 | 26 | -47 | 37 | 0 |
31 Mar 14 | 26 | -43 | 32 | 0 |
31 Dec 13 | 0 | -32 | 22 | 0 |
30 Sep 13 | 0 | -28 | 17 | 0 |
Quality Earnings: 524636 is currently unprofitable.
Growing Profit Margin: 524636 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524636 is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.
Accelerating Growth: Unable to compare 524636's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 524636 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 524636's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.